
Shaily Engineering Plastics Q1 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 1
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
2 of 3 growth signals are positive.
Full analysisRevenue guidance
Category 1- Targeting a 60-70% growth in healthcare revenue for the current financial year, indicating a substantial ramp-up in the pharma segment.
- Expecting to double overall revenue in the next 3 years, supported by increased capacity and new product launches.
- Pharma business projected to grow faster than the overall business, leading to margin improvement over a 3-year horizon.
- Adding capacity to manufacture an additional 20 million pens, with volume ramp-up expected over FY '24 to FY '26.
- Gradual improvement in utilization levels anticipated:
- - Current utilization expected around 50-55% for FY '24, with gradual improvement over the year.
- - Full utilization of new pharma facilities likely by second half of FY '25.
- New orders and products (e.g., GE Appliances, home furnishing) to contribute to growth starting Q4 FY '24 and FY '25.
- UK subsidiary foresees 2-3x revenue growth in the current financial year.
See what Shaily Engineering Plastics management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no specific mention of any current or planned fundraising through debt or equity in the provided transcript from the Q1 FY24 earnings call.
- Discussions focused on existing investments, capacity expansions, and business growth rather than new funding rounds.
- The company has already utilized funds raised in 2021 for enhancing capacities and building new healthcare facilities.
- No guidance or indication was provided about seeking additional debt or equity financing in the near term.
See what Shaily Engineering Plastics management said on order book — free account, 30 seconds.
Capex plans
Yes- Current year capex primarily focused on pharma facility and tool room; no large capex beyond this planned for the current year. (Page 17)
- Major pharma capex expected to complete between Q2 and Q3 of FY '24. (Page 8)
- Ramp-up of pharma facility expected over the next 4 to 6 quarters, with full utilization likely by the second half of FY '25. (Page 8)
- Post-improvement in utilization, future capex plans will depend on how utilization levels improve in other business segments. (Page 17)
- No incremental tooling capex anticipated for the INR 90 crore incremental orders; these orders are accretive at EBITDA and ROCE levels. (Page 15)
- Pharma investments made recently are aimed at accelerating faster revenue growth with increased IP contribution. (Pages 3, 8)
Track Shaily Engineering Plastics — get its next earnings analysis in your feed
How does Shaily Engineering Plastics rank vs peers in Consumer Durables?
Pro featureHow does Shaily Engineering Plastics rank in Consumer Durables?
Compare Shaily Engineering Plastics against every Consumer Durables company (Q1 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Shaily Engineering Plastics's management said in earlier quarters
Others in Consumer Durables this season
- Arham Tech (Q2 FY27)
Revenue from Operations for H1FY27: ₹85.48 Crores, an 87.34% year-on-year increase from ₹45.63 Crores in H1FY26 (Page 30, 29). Key investor presentation takeawa
- Khazanchi Jewell (Q2 FY27)
Q2 FY27 revenue from operations: ₹605.58 Crore, up 10.4% YoY (Q2 FY26: ₹548.60 Crore) [Page 7] . Key investor presentation takeaways from Khazanchi Jewellers Lt
- Uday Jewellery (Q2 FY27)
Q2 FY27 Total Income: ₹210.46 crore, up 30% year-on-year (YoY) . Key results statement takeaways from Uday Jewellery Industries Ltd's Q2 FY27 results statement
- Rajesh Exports (Q2 FY27)
Revenue from operations (net sales) for the quarter ended 30/09/2026: ₹2,895.85 million. Key results statement takeaways from Rajesh Exports Ltd's Q2 FY27 resul